跳至主要内容
临床试验/RPCEC00000079
RPCEC00000079已完成4 期

Impact of Human Recombinant Erithoropoietin(ior EPOCIM)in cancer patients with post Chemo and Radiotherapy induced anemia.

Center of Molecular Immunology(CIM)0 个研究点目标入组 338 人开始时间: 2009年7月3日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
338

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomized controlled trial. Masking: Open. Control group: Uncontrolled. Assignment: Single group. Purpose: Treatment

入排标准

年龄范围
18 至 none(—)
性别
All

入选标准

  • 1.Patients that fulfill the diagnostic criteria. 2.Patients with cytological and/or histological diagnosis of cancer in any localization that are receiving chemo and/or radiotherapy. 3.Patient with age over or equal to 18 years. 4.Patients of both sexes.

排除标准

  • 1.Patients with known hypersensitivity to products derived from superior cells or hypersensitivity to human albumin. 2.Pregnant or breastfeeding patients. 3.Patients with active hemorrhage or hemolysis. 4.Patients with non controlled arterial hypertension.

研究者

发起方
Center of Molecular Immunology(CIM)

相似试验